BridgeBio Pharma vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BridgeBio Pharma Inc (BBIO)

Q3 202622 Jun – 4 Sep 2026

▲3

BridgeBio Soars on Rival's Failure and Strong Attruby Data

AstraZeneca's ATTR-CM failure clears path for Attruby AstraZeneca's heart drug failed, removing a key competitor for BridgeBio's Attruby. Shares jumped 15% to a 52-week high as investors saw a clearer market for the treatment.
This was the main catalyst for the stock's rise in the quarter.
Attruby shows kidney benefits and strong revenue growth Attruby demonstrated kidney-protective benefits, and Q2 revenue surged 120% to $243.7 million. Imaging data also hinted at possible cardiac improvement, though that finding is exploratory.
These clinical and financial results reinforced the growth story.
Pipeline advances with three late-stage drugs nearing launch Three late-stage drugs are close to launch, two under FDA Priority Review. Infigratinib's Phase 3 data were published in NEJM, boosting confidence in the company's pipeline.
Pipeline progress supports future revenue potential.
Capital raise and Medicaid pricing deal create trade-offs BridgeBio raised $1 billion in preferred equity, strengthening its balance sheet. However, a Medicaid most-favored-nation pricing deal could reduce future U.S. revenue per prescription.
The capital boost is positive, but the pricing deal poses a risk to future profits.

August 202610 Aug – 4 Sep 2026

▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.
This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.
Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.
Pipeline launches are the next major growth catalyst and explain why investors look past current losses.
New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.
This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.
BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.
This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

Latest10 Aug – 4 Sep 2026

▲3▼1

Attruby Sales Boom, Three Launches Near, But Medicaid Price Cuts Loom

Attruby sales more than tripled, driving 120% revenue growth Second-quarter revenue hit $243.7 million, up 120% from a year ago, as Attruby U.S. sales more than tripled to $222.4 million. The drug is gaining first-line share in ATTR-CM, and real-world data show fewer heart hospitalizations than the rival tafamidis. More sales mean more cash to fund the business, which supports the stock.
This is the core commercial engine behind BBIO's revenue growth and the main reason the stock has risen.
Three pipeline drugs near launch, two with FDA Priority Review All three late-stage programs have been filed with the FDA. BBP-418 for LGMD2I/R9 has a decision date of Nov 27, 2026, and encaleret for ADH1 has one of May 8, 2027, both under Priority Review; oral infigratinib for achondroplasia targets a mid-2027 launch. New approvals would add revenue streams and reduce reliance on Attruby.
Pipeline launches are the next major growth catalyst and explain why investors look past current losses.
New heart-imaging data suggest acoramidis may reverse cardiac damage In the Phase 3 ATTRibute-CM study, 54% of acoramidis-treated patients had meaningful improvement in heart pumping function at 30 months versus 20% on placebo, and patients gained 38 more days alive outside the hospital. If confirmed, this could differentiate Attruby from rivals. The company cautions these are exploratory analyses, not proof of reversal.
This is fresh clinical evidence that could strengthen Attruby's competitive position and long-term sales.
BridgeBio signed a Medicaid most-favored-nation pricing deal BridgeBio is one of nine mid-sized drugmakers agreeing to match U.S. Medicaid prices to lower prices in other developed countries, in exchange for relief from import tariffs on ingredients. This could reduce future U.S. revenue per prescription, though state participation is optional and the full financial impact is not yet clear.
This is a new regulatory overhang that could pressure pricing and is a real counterweight to the positive sales story.

July 202622 Jun – 10 Jul 2026

▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.
This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.
New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.
This new clinical evidence differentiates Attruby from competitors and could drive future demand.
BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.
This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.
Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.
This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

22 Jun – 10 Jul 2026

▲4

BridgeBio's Attruby Strengthens as Rival Fails and Pipeline Advances

Attruby's competitive position strengthens after AstraZeneca's ATTR-CM failure AstraZeneca's Wainua failed a phase III ATTR-CM trial, removing a potential rival. BridgeBio's Attruby, already approved, gained a clearer path in a market worth over $20 billion. The stock jumped 15% to a 52-week high, adding $2.3 billion in market value.
This is the biggest new driver: a rival's failure directly boosts Attruby's outlook and sent BBIO to a 52-week high.
New data shows Attruby has unique kidney-protective benefits Post-hoc analyses showed acoramidis (Attruby) directly protects kidneys in ATTR-CM patients, a benefit not seen with other approved therapies. This could make Attruby a preferred treatment, supporting sales growth and a higher stock price.
This new clinical evidence differentiates Attruby from competitors and could drive future demand.
BridgeBio raises $1 billion in preferred equity to fund launches BridgeBio secured up to $1 billion from Sixth Street and KKR to accelerate launches of Attruby and three potential new drugs. The cash strengthens the balance sheet, reducing financing risk and supporting growth, which is positive for the stock.
This new capital raise gives BridgeBio funds to execute its launch plans, a key positive for future revenue.
Infigratinib Phase 3 data published in NEJM, supporting regulatory submission Positive Phase 3 results for oral infigratinib in achondroplasia were published in the New England Journal of Medicine, showing the largest height velocity improvement in any such trial. BridgeBio plans to file for FDA approval in Q3 2026, with launch expected in 2027.
This new data publication validates a key pipeline asset and brings a potential new blockbuster closer to market.

Regeneron Pharmaceuticals Inc (REGN)

Q3 20264 Jul – 1 Oct 2026

▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.
Strong financial results directly boost investor confidence and the stock price.
Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.
This major setback significantly impacted Regeneron's market value and reputation.
Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.
The deal has both positive financial aspects and negative implications for Dupixent economics.

September 202617 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest17 Sep – 1 Oct 2026

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.
This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.
Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.
A positive clinical readout in a major new market area is a key driver of future growth expectations.
Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.
Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.
Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.
It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 202627 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

27 Jul – 4 Sep 2026

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.
This is the period's biggest positive fundamental driver of REGN's value.
Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.
It is a concrete capital event that improves future profitability.
FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.
A new FDA approval is a fresh product and pipeline milestone for REGN.
Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.
This is the main negative overhang on REGN this period.

July 20264 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

4 Jul – 24 Jul 2026

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.
This is a new positive regulatory catalyst that could drive future revenue and investor optimism.
Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.
This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.
Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.
This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 202619 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.

19 Jun – 25 Jun 2026

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.
This is a new deal that adds to Regeneron's pipeline and potential future earnings.
Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.
Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.
FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.
This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.
AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.
This is a new competitive threat that could impact Regeneron's key product, Dupixent.